Shawn Terrell

I would love to see the Iranian people liberated from the repressive theocracy that has terrorized them for four decades. If Trumps war achieves that objective, I will withdraw my criticism of his war and praise him.

$HIMS Is a short squeeze actually coming, if so how high could the stock move? 👀📈 It has been disclosed that as of Feb 13th, 39% (81,010,101 shares) of $HIMS shares float is sold short🤯 Lets break down what this actually means and where it could go 👇🏽 A true short squeeze occurs when shorts are forced to cover (buy back shares) rapidly, driving the price higher, especially with catalysts like positive earnings surprises, news, retail momentum, or restricted borrow availability. $HIMS has seen elevated short interest amid volatility in its weight-loss offerings (GLP-1 compounding issues, lawsuits, regulatory scrutiny from FDA/ $NVO), contributing to a sharp drop from 2025 highs (over $70) to current levels around $15-16. Potential Upside in a Hypothetical Short SqueezeShort squeezes are unpredictable and rare, most high short interest stocks don't squeeze meaningfully, but HIMS has some classic ingredients: Mild/moderate squeeze scenario: Shorts cover partially due to a catalyst such as strong earnings beat, positive weight-loss updates, or a positive law suit update. This could push the stock 50-150% higher from $16, targeting $25-40 range. This aligns with some analyst consensus targets (around $30-39 average 12-month targets) implying 100-150% upside even without a full squeeze, as shorts add fuel. 📈 Aggressive/strong squeeze scenario (more speculative, GME/AMC-style): If buying volume surges (retail coordination, options gamma, or forced covers), and shorts panic, it could go much higher. With 81M shorts vs 208M float, covering a large portion could require buying equivalent to 30-40%+ of the float. Historical squeezes in mid-cap stocks with 30-50% short float have seen 3x-10x+ moves in short periods (though often brief and followed by reversals). From $16, that hypothetically could mean $50-100+ in extreme cases, especially if borrow rates spike or availability dries up further. 🚀 To conclude: - $HIMS Short interest has been high for months without a squeeze yet, and days to cover remain manageable. - Recent catalysts such as Q4 2025 earnings and 2026 guidance have been mixed with revenue growth projected but Q1 soft due to regulatory headwinds on compounded drugs. - Borrow rates appear low (under 1%), reducing squeeze pressure. - The stock is down heavily in 2026 already, with analysts mostly on "Hold" and seeing rebound potential but not extreme squeeze fireworks. Its important to understand though that the environment for a squeeze is never going to be 100% perfect... A full-blown squeeze could theoretically drive $HIMS well into the +$50 range , but a more realistic outcome if one triggers is a sharp but temporary spike to $30-50 before profit-taking. This is all hypothetical squeezes depend on momentum, not just numbers and shorting remains risky with high interest.